Clinton Edwards, MD
Nephrology · Jonesboro, ARNPI 1386611598
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,409 of the $7,818 with a category attached, or 82.0%. 35 manufacturers reported payments, led by Baxter Healthcare at 29.3% of the total. Among nephrology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $27.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$2K
- Vifor Pharma, Inc.$634
- AstraZeneca$577
- GSK$345
- Amgen$344
- OPKO Pharmaceuticals, LLC$342
- plus $3K from 29 others
Across 5 payments — averaging $20,538 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Baxter Healthcare$103K
What the payments were for
- Travel & lodging$96612%
- Food & beverage$6,40982%
- Education$4436%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 19 | $2,294 |
| Vifor Pharma, Inc. | 35 | $634 |
| AstraZeneca | 27 | $577 |
| GSK | 16 | $345 |
| Amgen(2 entities) | 19 | $344 |
| OPKO Pharmaceuticals, LLC | 15 | $342 |
| Otsuka America Pharmaceutical, Inc. | 17 | $317 |
| Novartis | 14 | $296 |
| Ardelyx, Inc. | 8 | $287 |
| Travere Therapeutics, Inc. | 20 | $267 |
| Novo Nordisk | 8 | $264 |
| Bayer | 15 | $247 |
| Akebia Therapeutics Inc | 9 | $178 |
| Boehringer Ingelheim | 9 | $146 |
| Vantive US Healthcare LLC | 2 | $138 |
| Fresenius USA Marketing, Inc. | 7 | $130 |
| Daiichi Sankyo Inc. | 6 | $116 |
| Aurinia Pharma U.S., Inc. | 4 | $102 |
| Veloxis Pharmaceuticals, Inc. | 1 | $96 |
| Calliditas Therapeutics US Inc. | 4 | $95 |
| Mallinckrodt Hospital Products Inc. | 4 | $90 |
| Lilly USA, LLC | 4 | $88 |
| Mallinckrodt Enterprises LLC | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Abiomed | 1 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| AbbVie | 1 | $30 |
| Boston Scientific | 2 | $30 |
| Averitas Pharma Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Acute$1,540
- Renal - PD$121
How this compares
$7,818 in reported general payments places this provider in the 90th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 21 | $64,490 |
| VelphoroSucroferric Oxyhydroxide | 26 | $63,046 |
| FarxigaDapagliflozin Propanediol | 79 | $51,062 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $33,258 |
| RayaldeeCalcifediol | 15 | $23,632 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $22,543 |
| Cinacalcet Hcl | 75 | $18,411 |
| Sevelamer Carbonate | 76 | $14,621 |
| Lanthanum Carbonate | 12 | $14,247 |
| Calcitriol | 635 | $8,856 |
| ProsolParenteral Amino Acid 20% No.1 | 30 | $5,652 |
| Calcium Acetate | 67 | $5,288 |
| Potassium Chloride | 96 | $1,516 |
| Midodrine Hcl | 15 | $1,492 |
| Bumetanide | 28 | $1,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $577 | $73,605116 claims |
| Fresenius USA Marketing, Inc.Velphoro | $130 | $63,04626 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $342 | $23,63215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Jonesboro
- Mohammed AlhajjiJonesboro$6K
- James MaxwellJonesboro$5K
- Michael MackeyJonesboro$1K
- Gerren HobbyJonesboro$377
- Adam WoodruffJonesboro$358
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
- Michael GerschHot Springs$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.